KR970702253A - 아미노 스틸바졸 유도체 및 의약(aminostilbazole derivative and medicine) - Google Patents

아미노 스틸바졸 유도체 및 의약(aminostilbazole derivative and medicine)

Info

Publication number
KR970702253A
KR970702253A KR1019960705560A KR19960705560A KR970702253A KR 970702253 A KR970702253 A KR 970702253A KR 1019960705560 A KR1019960705560 A KR 1019960705560A KR 19960705560 A KR19960705560 A KR 19960705560A KR 970702253 A KR970702253 A KR 970702253A
Authority
KR
South Korea
Prior art keywords
carbon atoms
amino
phenyl
hydrogen
alkyl
Prior art date
Application number
KR1019960705560A
Other languages
English (en)
Other versions
KR100293867B1 (ko
Inventor
히로요시 히다카
아키라 마츠우라
마사토 마츠다
Original Assignee
히로요시 히다카
아만 히데아키
니뽄 신야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 히로요시 히다카, 아만 히데아키, 니뽄 신야쿠 가부시키가이샤 filed Critical 히로요시 히다카
Publication of KR970702253A publication Critical patent/KR970702253A/ko
Application granted granted Critical
Publication of KR100293867B1 publication Critical patent/KR100293867B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

본 발명은 각종 악성종양의 치료에 유용한 하기 화학식(1)로 표시되는 아미노스틸바졸 유도체 또는 그 수화물 및 그 염에 관한 것이다:
식 중, R1및 R2는 각각 수소 등을 나타내고; R3, R4, R13및 R4는 각각 수소, C1-C3아실, 할로겐, 히드록시 등을 나타내고; R5는 수소, 히드록실화된 C1-C3알킬 등을 나타내고; R6는 C1-C3알콕시-치환된 벤젠설포닐 등을 나타내고; 고리 Y는 페닐 등을 나타내고; 고리 Z는 4-피리딜 및 그것의 옥사이드등을 나타낸다.

Description

아미노 스틸바졸 유도체 및 의약(AMINOSTILBAZOLE DERIVATlVE AND MEDICINE)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 하기 화학식(1)로 표시되는 화합물 또는 그 수화물 및 그 염:
    식 중, R1및 R2는 동일하거나 또는 상이한 것으로, 각각 수소, 탄소수 1∼6의 알킬, 탄소수 1∼6의 아실, 시아노 또는 -COOR(R은 수소 또는 탄소수 1∼6의 알킬)을 나타내고, R3, R4, R13및 R14및 동일하거나 또는 상이한 것으로, 각각 수소, 탄소수 1∼6의 알킬, 탄소수 1∼6의 알콕시, 탄소수 1∼6의 할로알콕시, 탄소수 1∼6의 아실, 탄소수 1∼6의 아실옥시, 히드록시, 할로겐, 니트로, 시아노, 아미노, 탄소수 1∼6의 아실아미노, 탄소수 l∼6의 아미노알켈옥시 또는, 알킬 부분의 탄소수가 1∼6의 모르폴리노알킬옥시를 나타내며, 또한, R3과 R13, 또한 R4와 R14가 함께 메틸렌디옥시를 나타낼 수 있고, R5는 ① 수소, ② 할로겐, 아미노, 탄소수 l∼6의 모노알킬아미노, 탄소수 1∼6의 디알킬아미노, 모르폴리노, 탄소수 1∼6의 알콕시 또는 히드록시로 임의 치환되는 탄소수 1∼6의 알킬, ③ 할로겐으로 임의 치환되는 탄소수 2∼6의 알케닐, ④ 탄소수 2∼6의 알키닐 또는 ⑤ 탄소수 1∼6의 아실을 나타내고, R6은 ① 탄소수 1∼6의 알킬, 탄소수 1∼6의 알콕시 또는
    할로겐으로 임의 치환되는 탄소수 7∼11의 아로일 또는 ② 탄소수 1∼6의 알킬, 탄소수 1∼6의 알콕시, 탄소수 1∼6의 할로알콕시, 히드록시, 니트로 또는 할로겐으로 임의 치환되는 탄소수 6∼10의 아릴설포닐을 나타내고, A, B, G, Q 및 X는 동일하거나 또는 상이한 것으로, 각각 N, CH, N-, O 또는 N, -(R7)[(여기서 R7은 탄소수 l∼6의 알킬 또는 탄소수 7∼14의 아릴알킬; E-는 할로겐이온, 염소산이온, 질산이온과 같은 음이온을 나타냄)를 나타내고, 단, A, B, G가 동시에 N인 경우 및 A, B, G, Q, X가 동시에 CH인 경우는 제외되며, Y, Z는 각각 고리를 나타낸다.
  2. 제1항에 있어서, R1및 R2가 각각 수소이고; R3, R4, R13및 R14가 동일하거나 또는 상이한 것으로, 각각 수소, 탄소수 1∼3의 아실, 할로겐 또는 히드록시이고; R5가 수소 또는 히드록시로 치환된 탄소수 1∼3의 알킬이고; R6이 탄소수 1∼3의 알콕시로 치환된 벤젠설포닐이고; Y 고리가 페닐이고; Z 고리는 4-피리딜 또는 그것의 옥사이드인 것을 특징으로 하는 화합물.
  3. 제1항에 있어서, R1및 R2가 각각 수소이고; R3, R4, R13및 R14가 동일하거나 또는 상이한 것으로, 각각 수소, 아세틸, 불소 또는 히드록시이고; R5가 수소 또는 히드록시로 치환된 에틸이고; R6이 메톡시로 치환된 벤젠설포닐이고; Y 고리가 페닐이고; Z 고리가 4-피리딜인 것을 특징으로 하는 화합물.
  4. 제1항에 있어서, (E)-4-[2-[2-(p-메톡시페닐)설포닐]아미노]페닐]에테닐]피리딘, (E)-4-[2-[[[2-(p-메톡시페닐)설포닐]아미노]페닐]에테닐]피리딘 1-옥사이드, (E) -4-[2-[2-[N-(2-히드록시에틸)-N-(p-에톡시페닐)설포닐]아미노]페닐]에테닐]피리딘 1-옥사이드, (E)-4-[2-[2-[N-(2-히드록시에틸)-N-[p-메톡시페닐)설포닐]아미노]페닐]에테닐]피리딘 또는 (E)-4-[2-[2-[N-아세틸-N-(p-메톡시페닐)설포닐]아미노]메틸]에테닐]피리던 1-옥사이드 및 그 염으로부터 선택되는 것을 특징으로 하는 화합물.
  5. 제1항에 있어서, (E)-4-[2-[[[2-(p-메톡시페닐)설포닐]아미노]페닐]에테닐]피리딘, (E)-4-[2-[2-[N-(2-히드록시에틸)-N-[p-메톡시페닐)설포닐]아미노]페닐]에테닐]피리딘 1-옥사이드 또는 (E) -4-[2-[2-[N-(2-히드록시에틸)-N-(p-메톡시페닐)설포닐]아미노]페닐]에테닐]피리딘 및 그염으로 부터 선택되는 것을 특징으로 하는 화합물.
  6. 제1항 내지 제5항 중 어느 한 항의 화합물 또는 그것의 수화물 또는 그 염을 유효 성분으로 포함하는 약학 조성물.
  7. 제1항 내지 제5항 중 어느 한 항의 화합물 또는 그것의 수화물 또는 그 염을 유효 성분으로 포함하는 항암제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960705560A 1994-04-06 1995-04-05 아미노스틸바졸유도체및의약 KR100293867B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP94-068252 1994-04-06
JP6825294 1994-04-06
PCT/JP1995/000658 WO1995027699A1 (fr) 1994-04-06 1995-04-05 Derive d'aminostilbazole et medicament

Publications (2)

Publication Number Publication Date
KR970702253A true KR970702253A (ko) 1997-05-13
KR100293867B1 KR100293867B1 (ko) 2001-09-17

Family

ID=13368389

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960705560A KR100293867B1 (ko) 1994-04-06 1995-04-05 아미노스틸바졸유도체및의약

Country Status (14)

Country Link
US (1) US5972976A (ko)
EP (1) EP0754682B9 (ko)
JP (1) JP3080405B2 (ko)
KR (1) KR100293867B1 (ko)
CN (1) CN1053658C (ko)
AT (1) ATE207057T1 (ko)
CA (1) CA2187214C (ko)
DE (1) DE69523298T2 (ko)
DK (1) DK0754682T3 (ko)
ES (1) ES2165911T3 (ko)
PT (1) PT754682E (ko)
RU (1) RU2138482C1 (ko)
TW (1) TW308586B (ko)
WO (1) WO1995027699A1 (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1072688B1 (en) * 1998-04-15 2004-06-30 Hiroyoshi Hidaka Method for in vivo detecting a target protein gene by a drug
EP1079851B1 (en) * 1998-05-12 2007-07-04 Greenville Hospital System Use of anti-prolactin agents to treat cancer
WO2000064875A1 (fr) * 1999-04-23 2000-11-02 Nippon Shinyaku Co., Ltd. Procede de pulverisation
US6521658B1 (en) 1999-05-28 2003-02-18 Abbott Laboratories Cell proliferation inhibitors
MXPA02005866A (es) * 1999-12-14 2002-10-23 Nippon Shinyaku Co Ltd Derivados de heterociclo y drogas.
JP2004359545A (ja) * 2001-03-08 2004-12-24 D Western Therapeutics Institute 抗癌剤耐性克服剤
KR100801121B1 (ko) * 2001-04-10 2008-02-05 니뽄 신야쿠 가부시키가이샤 만성 관절 류마티즘 치료제
EP1382335A4 (en) 2001-04-26 2006-05-24 Nippon Shinyaku Co Ltd PHARMACEUTICAL PRODUCTS
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
FR2838437B1 (fr) * 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
EP1547596A4 (en) * 2002-09-06 2008-11-19 Western Therapeutics Inst Inc MEDICAL COMPOSITION AND METHOD FOR THE TREATMENT OF MALIGNANT TUMORS AND THE USE THEREOF
WO2006078941A2 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Novel sirtuin activating compounds and methods of use thereof
WO2007137196A2 (en) * 2006-05-19 2007-11-29 Threshold Pharmaceuticals, Inc. Tubulin binding anti cancer compounds and prodrugs thereof
US20100198262A1 (en) * 2009-01-30 2010-08-05 Mckinley Laurence M Axial offset bone fastener system
US9884842B2 (en) 2013-04-19 2018-02-06 Bioventures, Llc Combretastatin analogs
AU2014363415B2 (en) 2013-12-13 2019-08-29 Eurochem Agro Gmbh Fertilizer mixture containing nitrification inhibitor
CA2940694A1 (en) 2014-03-31 2015-10-08 Board Of Trustees Of The University Of Arkansas Disubstituted triazole analogs
CN112110829B (zh) * 2019-06-19 2023-08-01 复旦大学 一种能结合α-突触核蛋白聚集体的小分子化合物、其制备方法及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2790926B2 (ja) * 1990-08-20 1998-08-27 エーザイ株式会社 スルホンアミド誘導体
EP0472053B1 (en) * 1990-08-20 1998-06-17 Eisai Co., Ltd. Sulfonamide derivatives
JP2692467B2 (ja) * 1991-12-09 1997-12-17 ダイキン工業株式会社 空調制御装置の電力供給装置
US5534654A (en) * 1991-12-10 1996-07-09 Shionogi & Co., Ltd. Aromatic-sulfonamide-type hydroxamic acid derivative

Also Published As

Publication number Publication date
CA2187214C (en) 2002-03-12
EP0754682B9 (en) 2003-09-17
CA2187214A1 (en) 1995-10-19
PT754682E (pt) 2002-03-28
CN1145066A (zh) 1997-03-12
DE69523298T2 (de) 2002-06-27
DK0754682T3 (da) 2002-02-04
MX9604540A (es) 1997-09-30
EP0754682A1 (en) 1997-01-22
US5972976A (en) 1999-10-26
KR100293867B1 (ko) 2001-09-17
WO1995027699A1 (fr) 1995-10-19
DE69523298D1 (de) 2001-11-22
TW308586B (ko) 1997-06-21
JP3080405B2 (ja) 2000-08-28
RU2138482C1 (ru) 1999-09-27
EP0754682B1 (en) 2001-10-17
ATE207057T1 (de) 2001-11-15
ES2165911T3 (es) 2002-04-01
CN1053658C (zh) 2000-06-21
EP0754682A4 (en) 1998-03-04

Similar Documents

Publication Publication Date Title
KR970702253A (ko) 아미노 스틸바졸 유도체 및 의약(aminostilbazole derivative and medicine)
ATE152719T1 (de) Chinolylbenzofuran derivate als leukotrien- antagonisten
NO900991L (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(l-piperazinyl)-4-fenylcycloalkanopyridin-derivater
TR200100300T2 (tr) Sitokinlerin üretiminde engelleyici olarak kullanışlı amid türevleri
DE69930926D1 (de) Benzolsulfonamid-derivate und ihre anwendung als arzneimittel
HUT54149A (en) Process for producing new 3-brackets open 4-(1-substituted-4-piperazinyl)-butyl brackets closed-4-thiazolidinone derivatives and pharmaceutical compositions comprising such compounds
ES2088933T3 (es) Derivados de pirazol, procedimientos para su preparacion y composicion farmaceutica que los contiene.
NO986055D0 (no) Nye heterocykliske forbindelser, deres fremstilling, farmas÷ytiske preparat
NL930018I1 (nl) (Piperidinylalkyl) chinazolinederivaten,werkwijze voor hun bereiding en farmaceutische preparaten die ze bevatten
EA200401172A1 (ru) Производные n-[фенил(пиперидин-2-ил)метил]бензамида, способ их получения и их применение в терапии
AU5932294A (en) New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
HUP0300721A2 (hu) Antibakteriális hatású (amino-piperidino)-kinolinok és aza-izoszter analógjaik, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DK0656353T3 (da) Aminoquinolinderivater med en virkning mod malariafremkaldere
RU96121800A (ru) Производное аминостильбазола и лекарственный препарат
SE0101579D0 (sv) New compounds
DE69231445D1 (de) Triazole enthaltende antifungizide mittel
SE9703378D0 (sv) New compounds
ATE276257T1 (de) Pyrazinonderivate
DK1022276T3 (da) Epoxysuccinamidderivater
CA2281918A1 (en) Oxazolidines as 5-ht2a-antagonists
DE69512208D1 (de) Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren
ATE195517T1 (de) Chinolinonderivate und diese enthaltende antiallergische zusammensetzungen
ES2165410T3 (es) Nuevas 5-(ariloxi-metil)-oxazolinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
DE69600329D1 (de) Benzothiazol-Derivate
ATE215075T1 (de) Hydroxylamin-derivate mit anti-ischämischer wirkung und pharmazeutische zusammensetzungen diese enthaltend

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
FPAY Annual fee payment

Payment date: 20130321

Year of fee payment: 13

FPAY Annual fee payment

Payment date: 20140319

Year of fee payment: 14

EXPY Expiration of term